NASDAQ:ALBO - Albireo Stock Price, Price Target & More

Get Started

$32.86 +0.04 (+0.12 %)

(As of 05/20/2018 03:40 PM ET)

Previous Close$32.86

Today's Range$32.32 - $33.34

52-Week Range$15.31 - $39.87

Volume55,790 shs

Average Volume63,798 shs

Market Capitalization$392.41 million

P/E Ratio-10.43

Dividend YieldN/A

Beta1.61

About Albireo (NASDAQ:ALBO)

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The company's clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ALBO

CUSIPN/A

Webwww.albireopharma.com

Phone857-254-5555

Debt

Debt-to-Equity RatioN/A

Current Ratio27.27

Quick Ratio27.27

Price-To-Earnings

Trailing P/E Ratio-10.43

Forward P/E Ratio38.66

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book Value$13.41 per share

Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)($3.15)

Net Income$-24,410,000.00

Net MarginsN/A

Return on Equity-21.17%

Return on Assets-17.56%

Miscellaneous

Employees22

Outstanding Shares11,940,000

Albireo (NASDAQ:ALBO) Frequently Asked Questions

What is Albireo's stock symbol?

Albireo trades on the NASDAQ under the ticker symbol "ALBO."

How were Albireo's earnings last quarter?

Albireo (NASDAQ:ALBO) posted its quarterly earnings results on Thursday, May, 17th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $3.75 by $3.90. The biopharmaceutical company earned $11.20 million during the quarter, compared to analysts' expectations of $55.33 million. View Albireo's Earnings History.

What price target have analysts set for ALBO?

5 equities research analysts have issued 1 year target prices for Albireo's stock. Their forecasts range from $50.00 to $92.00. On average, they anticipate Albireo's share price to reach $63.75 in the next year. View Analyst Ratings for Albireo.

What are Wall Street analysts saying about Albireo stock?

Here are some recent quotes from research analysts about Albireo stock:

1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (3/30/2018)
2. Needham & Company LLC analysts commented, "Albireo mgmt hosted a 4Q17 conference call today to provide a corporate update. Company remains on track for initiation of Phase 3 testing of IBAT inhibitor A4250 in Progressive Familiar Intrahepatic Cholestasis (PFIC) in the near future. As a reminder, Albireo presented encouraging data from a Phase 2 trial in rare pediatric cholestatic liver diseases, including PFIC, in 2017. Mgmt guided for Phase 3 top-line results by YE19, w/ regulatory submissions shortly thereafter. Albireo also plans to evaluate elobixibat in Non-Alcoholic Steatohepatitis (NASH), although not until early 2019. Evaluation of A4250 in other rare pediatric cholestatic liver diseases and testing of A3384 in Bile Acid Malabsorption is still planned, but deprioritized in order to focus on A4250 in PFIC. We believe stock is undervalued and reiterate BUY." (3/15/2018)
3. Wedbush analysts commented, "Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders." (1/3/2018)
4. Cowen Inc analysts commented, "Albireo reported 3Q earnings today and provided a brief summary of recent progress." (11/17/2017)

Who are some of Albireo's key competitors?

Some companies that are related to Albireo include ARMO BioSciences (ARMO), PTC Therapeutics (PTCT), Innoviva (INVA), Zogenix (ZGNX), Radius Health (RDUS), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Apellis Pharmaceuticals (APLS), Endo International (ENDP), TherapeuticsMD (TXMD), Impax Laboratories (IPXL), Theravance Biopharma (TBPH), Myovant Sciences (MYOV), Mallinckrodt (MNK) and Immuron (IMRN).

Who are Albireo's key executives?

Albireo's management team includes the folowing people:

Mr. Ronald H. W. Cooper, Chief Exec. Officer, Pres and Director (Age 55)
Dr. Jan P. Mattsson Ph.D., Chief Operating Officer (Age 54)
Mr. Peter A. Zorn, Chief Corp. Officer, Gen. Counsel & Sec. (Age 48)
Dr. Per-Goran Gillberg Ph.D., Co-Founder and VP of Devel.
Mr. Thomas A. Shea MBA, Chief Financial Officer and Treasurer (Age 58)

Has Albireo been receiving favorable news coverage?

News articles about ALBO stock have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Albireo earned a media sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.27 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Albireo's major shareholders?

Albireo's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (4.59%), Federated Investors Inc. PA (2.60%), BVF Inc. IL (1.88%), Millennium Management LLC (1.30%), Heartland Advisors Inc. (0.76%) and Chicago Capital LLC (0.76%). Company insiders that own Albireo stock include Life Sciences Maste Perceptive, Phase4 Partners Ltd and Plc Astrazeneca. View Institutional Ownership Trends for Albireo.

Which major investors are buying Albireo stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Artal Group S.A., BVF Inc. IL, Millennium Management LLC, Heartland Advisors Inc., Chicago Capital LLC, BlackRock Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Albireo.

How do I buy shares of Albireo?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albireo's stock price today?

One share of ALBO stock can currently be purchased for approximately $32.86.

How big of a company is Albireo?

Albireo has a market capitalization of $392.41 million. The biopharmaceutical company earns $-24,410,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Albireo employs 22 workers across the globe.

How can I contact Albireo?

Albireo's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]

MarketBeat Community Rating for Albireo (ALBO)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		124 (Vote Outperform)
Underperform Votes:		140 (Vote Underperform)
Total Votes:		264

MarketBeat's community ratings are surveys of what our community members think about Albireo and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Albireo (NASDAQ:ALBO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Albireo in the last 12 months. Their average twelve-month price target is $63.75, suggesting that the stock has a possible upside of 94.00%. The high price target for ALBO is $92.00 and the low price target for ALBO is $50.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$63.75	$63.75	$66.6667	$61.6667
Price Target Upside:	94.00% upside	88.83% upside	94.36% upside	137.27% upside

Albireo (NASDAQ:ALBO) Consensus Price Target History

Price Target History for Albireo (NASDAQ:ALBO)

Albireo (NASDAQ:ALBO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/20/2018	Wedbush	Reiterated Rating	Outperform	$63.00	Low
4/20/2018	Jefferies Group	Initiated Coverage	Buy	$50.00	High
3/15/2018	Needham & Company LLC	Initiated Coverage	Buy	$50.00	High
11/17/2017	Cowen	Reiterated Rating	Buy		N/A
11/15/2017	Roth Capital	Initiated Coverage	Buy ➝ Buy	$92.00	N/A
2/16/2017	Ladenburg Thalmann	Initiated Coverage	Buy		N/A
1/25/2017	William Blair	Initiated Coverage	Outperform		N/A

(Data available from 5/20/2016 forward)

Albireo (NASDAQ:ALBO) Earnings History and Estimates Chart

Earnings by Quarter for Albireo (NASDAQ:ALBO)

Albireo (NASDAQ:ALBO) Earnings Estimates

2018 EPS Consensus Estimate: $0.94

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$3.57	$4.05	$3.81
Q2 2018	2	($0.90)	($0.86)	($0.88)
Q3 2018	2	($0.99)	($0.87)	($0.93)
Q4 2018	2	($1.07)	($1.06)	($1.07)

Albireo (NASDAQ ALBO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/17/2018	Q1 2018	$3.75	($0.15)	$55.33 million	$11.20 million	View	Listen
3/15/2018	Q4 2017	($0.78)	($0.55)			View	Listen
11/14/2017	Q3 2017	($0.85)	($0.73)			View	N/A
8/21/2017	6/30/2017	($0.84)	($0.86)			View	N/A
5/10/2017	Q2 2017	($1.1050)	($1.06)			View	N/A
8/11/2016	Q216		($0.05)			View	N/A
5/9/2016	Q2	($0.04)	($0.09)			View	N/A
2/16/2016	Q1	($0.08)	($0.05)			View	N/A
12/17/2015	Q315	($0.11)	($0.05)			View	Listen
8/13/2015	Q3	($0.10)	($0.12)			View	Listen
5/6/2015	Q215	($0.23)	($0.27)			View	N/A
2/12/2015	Q115	($0.18)	($0.20)			View	N/A
12/17/2014	Q414	($0.27)	($0.16)			View	N/A
8/11/2014	Q2 2014	($0.26)	($0.15)			View	N/A
5/13/2014	Q114	($0.26)	($0.29)			View	N/A
2/6/2014	Q4	($0.19)	($0.20)			View	N/A
12/18/2013	Q4	($0.30)	($0.04)			View	Listen
8/12/2013	Q3 2013	($0.37)	($0.66)			View	N/A
5/8/2013	Q2 2013	($0.43)	($0.37)			View	N/A
2/12/2013	Q4 2012	($12.91)	($12.61)			View	N/A
12/18/2012	Q3 2012	($13.81)	($12.31)			View	N/A
8/8/2012	Q2 2012	($16.22)	($13.39)			View	N/A
5/10/2012	Q1 2012	($18.02)	($13.33)			View	N/A
2/8/2012	Q4 2011	($16.82)	($13.93)			View	N/A
12/6/2011	Q3 2011	($20.42)	($15.86)			View	N/A
8/4/2011	Q2 2011	($25.23)	($17.66)			View	N/A
5/5/2011	Q1 2011	($31.23)	($24.74)			View	N/A
2/3/2011	Q4 2010	($33.63)	($24.14)			View	N/A
12/9/2010	Q3 2010	($44.44)	($37.24)			View	N/A
8/5/2010	Q2 2010	($48.05)	($43.24)			View	N/A
5/6/2010	Q1 2010	($50.45)	($52.37)			View	N/A
2/4/2010	Q4 2009	($51.65)	($56.10)			View	N/A
12/14/2009	Q3 2009	($60.06)	($52.97)			View	N/A
8/7/2009	Q2 2009	($61.26)	($56.34)			View	N/A
5/7/2009	Q1 2009	($50.45)	($58.86)			View	N/A
2/5/2009	Q4 2008	($50.45)	($50.81)			View	N/A
12/10/2008	Q3 2008	($54.05)	($63.66)			View	N/A
8/6/2008	Q2 2008	($54.05)	($51.29)			View	N/A
5/9/2008	Q1 2008	($56.46)	($52.13)			View	N/A
2/14/2008	Q4 2007	($54.05)	($65.59)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Albireo (NASDAQ:ALBO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Albireo (NASDAQ ALBO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 29.35%

Insider Trading History for Albireo (NASDAQ:ALBO)

Institutional Ownership by Quarter for Albireo (NASDAQ:ALBO)

Albireo (NASDAQ ALBO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
1/30/2018	Phase4 Partners Ltd	Major Shareholder	Sell	100,000	$34.44	$3,444,000.00
1/25/2018	Life Sciences Maste Perceptive	Major Shareholder	Buy	275,000	$33.00	$9,075,000.00
12/1/2017	Plc Astrazeneca	Major Shareholder	Sell	500,000	$21.40	$10,700,000.00
12/20/2013	Brian Jg Pereira	Director	Sell	4,734	$2.26	$10,698.84

(Data available from 1/1/2013 forward)

Albireo (NASDAQ ALBO) News Headlines

Source:

Date	Headline
	Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues www.streetinsider.com - May 18 at 10:26 AM
	Albireo (ALBO) Issues Quarterly Earnings Results, Beats Expectations By $0.95 EPS www.americanbankingnews.com - May 18 at 8:15 AM
	Albireo (ALBO) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - May 18 at 3:48 AM
	Albireo (ALBO) Lifted to "Hold" at BidaskClub www.americanbankingnews.com - May 17 at 4:53 PM
	BRIEF-Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15 www.reuters.com - May 17 at 9:47 AM
	Albireo Provides First Quarter 2018 Business Update finance.yahoo.com - May 17 at 9:47 AM
	BRIEF-Albireo Enrolls First Patient In Phase 3 PFIC Trial Of A4250 www.reuters.com - May 16 at 9:48 AM
	Albireo Pharma (ALBO) Reports First Patient Enrollment in Phase 3 PFIC Trial of A4250 www.streetinsider.com - May 16 at 9:48 AM
	Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250 finance.yahoo.com - May 16 at 9:48 AM
	Albireo (ALBO) Upgraded at BidaskClub www.americanbankingnews.com - May 11 at 9:16 PM
	Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018 finance.yahoo.com - May 9 at 9:36 AM
	$55.33 Million in Sales Expected for Albireo (ALBO) This Quarter www.americanbankingnews.com - May 8 at 2:26 AM
	Brokerages Expect Albireo (ALBO) to Post $3.75 Earnings Per Share www.americanbankingnews.com - May 6 at 7:33 PM
	Jefferies Starts Albireo Pharma (ALBO) at Buy www.streetinsider.com - May 5 at 9:52 AM
	Albireo (ALBO) Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - May 5 at 12:29 AM
	Albireo (ALBO) Rating Increased to Strong-Buy at ValuEngine www.americanbankingnews.com - May 4 at 12:54 AM
	Albireo to Present at Deutsche Bank 43rd Annual Health Care Conference finance.yahoo.com - April 30 at 9:44 AM
	Energy Management Control Corporation Joins Albireo Energy www.prnewswire.com - April 25 at 4:33 PM
	Albireo Pharma, Inc. (ALBO) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 23 at 3:34 AM
	Brokerages Expect Albireo Pharma, Inc. (ALBO) Will Post Quarterly Sales of $55.00 Million www.americanbankingnews.com - April 21 at 2:35 AM
	Albireo Pharma (ALBO) Earns "Outperform" Rating from Wedbush www.americanbankingnews.com - April 20 at 4:17 PM
	Albireo Pharma (ALBO) Receives New Coverage from Analysts at Jefferies Group www.americanbankingnews.com - April 20 at 10:25 AM
	Analysts Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of $3.81 Per Share www.americanbankingnews.com - April 19 at 5:22 PM
	BidaskClub Lowers Albireo Pharma (ALBO) to Sell www.americanbankingnews.com - April 19 at 11:10 AM
	Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting finance.yahoo.com - April 19 at 9:33 AM
	Albireo Pharma (ALBO) Receives New Coverage from Analysts at Needham & Company LLC www.americanbankingnews.com - April 17 at 6:29 PM
	Albireo Pharma (ALBO) Annoucnes Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver ... www.streetinsider.com - April 16 at 9:27 AM
	Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The ... globenewswire.com - April 16 at 9:27 AM
	Albireo Pharma (ALBO) Downgraded by ValuEngine to "Sell" www.americanbankingnews.com - April 8 at 2:04 PM
	Albireo Pharma, Inc. (ALBO) Expected to Announce Quarterly Sales of $55.00 Million www.americanbankingnews.com - April 4 at 2:30 AM
	$3.81 Earnings Per Share Expected for Albireo Pharma, Inc. (ALBO) This Quarter www.americanbankingnews.com - April 2 at 5:16 PM
	Albireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - March 30 at 4:32 PM
	Albireo Pharma, Inc. to Post Q1 2018 Earnings of $3.57 Per Share, Wedbush Forecasts (ALBO) www.americanbankingnews.com - March 30 at 6:50 AM
	Albireo Pharma (ALBO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 29 at 4:23 PM
	Albireo Pharma, Inc. (ALBO) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 29 at 3:24 AM
	Albireo Pharma (ALBO) to Present Clinical Data on A4250 at The International Liver Congress www.streetinsider.com - March 28 at 4:21 PM
	Albireo Pharma (ALBO) Lowered to Hold at BidaskClub www.americanbankingnews.com - March 28 at 11:55 AM
	Albireo Pharma's (ALBO) "Outperform" Rating Reaffirmed at Wedbush www.americanbankingnews.com - March 28 at 11:11 AM
	Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018 finance.yahoo.com - March 28 at 9:48 AM
	Albireo Pharma (ALBO) Upgraded to Buy by BidaskClub www.americanbankingnews.com - March 26 at 9:57 AM
	Albireo Pharma (ALBO) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 25 at 9:16 PM
	Albireo Pharma (ALBO) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - March 24 at 1:54 PM
	Albireo to Present at 17th Annual Needham & Company Healthcare ... - GlobeNewswire (press release) globenewswire.com - March 21 at 4:20 PM
	Albireo to Present at 17th Annual Needham & Company Healthcare Conference - Nasdaq www.nasdaq.com - March 21 at 10:44 AM
	Albireo to Present at 17th Annual Needham & Company Healthcare Conference finance.yahoo.com - March 21 at 10:44 AM
	Albireo Pharma (ALBO) Lifted to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 19 at 5:02 PM
	Q1 2018 EPS Estimates for Albireo Pharma, Inc. (ALBO) Raised by William Blair www.americanbankingnews.com - March 19 at 1:56 AM
	Albireo Reports Fourth Quarter and Year-End 2017 Financial Results - GlobeNewswire (press release) globenewswire.com - March 17 at 9:48 AM
	BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results www.reuters.com - March 15 at 4:51 PM
	Albireo Pharma (ALBO) Now Covered by Analysts at Needham & Company LLC www.americanbankingnews.com - March 15 at 4:20 PM

Albireo (NASDAQ:ALBO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Albireo (NASDAQ:ALBO) Income Statement, Balance Sheet and Cash Flow Statement

Albireo (NASDAQ ALBO) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff